首页>
外国专利>
Antibody specifically binding to the N-terminal region of lysyl-tRNA synthetase exposed at cell outer membrane
Antibody specifically binding to the N-terminal region of lysyl-tRNA synthetase exposed at cell outer membrane
展开▼
机译:抗体特异性结合暴露于细胞外膜的赖氨酰tRNA合成酶的N端区域
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to an antibody that specifically binds to the N-terminal region of a lysyl-tRNA synthetase exposed to the outer cell membrane and the use thereof, and more specifically, a specific CDR (complementarity determining region) sequence described herein. An antibody or fragment thereof having a lysyl-tRNA synthetase (KRS, Lysyl-tRNA synthetase) N-terminal specifically binding to an epitope comprising the sequence of SEQ ID NO: 97, and cancer metastasis of the antibody or fragment It is for suppression purpose and cancer diagnosis use. Since the antibody or fragments according to the present invention have a very good specific binding ability to the KRS N-terminal region exposed to the outer membrane, a disease known as a disease (eg, cancer) accompanying the specific behavior of KRS Available for diagnosis. In addition, since it is specifically targeted to the KRS N-terminal region in vivo, it can be used as a therapeutic agent because it has an excellent effect of inhibiting cancer metastasis by inhibiting the interaction between the laminin receptor and the KRS N-terminal region, so it can be used as a therapeutic agent, making it industrially applicable Big.
展开▼
机译:本发明涉及与暴露于细胞外膜的赖氨酰-tRNA合成酶的N-末端区域特异性结合的抗体及其用途,更具体地说,是本文所述的特异性CDR(互补决定区)序列。具有与包含SEQ ID NO:97的序列的表位特异性结合的赖氨酰-tRNA合成酶(KRS,赖氨酰-tRNA合成酶)N-末端的抗体或其片段,以及该抗体或片段的癌症转移。和癌症诊断用途。由于本发明的抗体或片段与暴露于外膜的KRS N末端区域具有非常良好的特异性结合能力,因此伴随着KRS的特定行为的称为疾病的疾病(例如,癌症)可用于诊断。此外,由于它是体内特异性靶向KRS N末端区域,因此可以用作治疗剂,因为它具有通过抑制层粘连蛋白受体与KRS N末端之间的相互作用来抑制癌症转移的优异作用。区域,因此可以用作治疗剂,使其在工业上具有很大的适用性。
展开▼